List of Lysteda drug patents

Lysteda is owned by Amring Pharms.

Lysteda contains Tranexamic Acid.

Lysteda has a total of 8 drug patents out of which 0 drug patents have expired.

Lysteda was authorised for market use on 13 November, 2009.

Lysteda is available in tablet;oral dosage forms.

Lysteda can be used as treatment of cyclic heavy menstrual bleeding.

The generics of Lysteda are possible to be released after 04 March, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9060939 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US7947739 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US8022106 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US8273795 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US8487005 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US8791160 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US8957113 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

US8809394 AMRING PHARMS Tranexamic acid formulations
Mar, 2025

(2 years from now)

Drugs and Companies using TRANEXAMIC ACID ingredient

Market Authorisation Date: 13 November, 2009

Treatment: Treatment of cyclic heavy menstrual bleeding

Dosage: TABLET;ORAL

How can I launch a generic of LYSTEDA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in